Dual-flow Lab-on-a-Chip diagnostics with AI-assisted smartphone readout. Under 15 minutes, under $1 per test, no laboratory required.
The only WHO-endorsed urine-based POC test detects only 40 to 50% of cases,
restricting it to severely immunocompromised HIV-positive patients.
A vertically stacked dual-flow architecture that delivers enzyme-amplified,
naked-eye-readable results from a single user step. No reader, no lab, no compromise.
Built on the same dual-flow architecture,
optimized for two distinct global health priorities.
Catching latent tuberculosis in 15 minutes, anywhere.
Quantifying cortisol at the point of care.
Every benefit is anchored in a published or in-progress data point.
Built and validated across three institutions.
TB-LAM LoD (current)
cTnI LoD (platform)
WHO TPP sensitivity threshold
In Collaboration With
University of Cincinnati,
Mississippi State University,
UC 1819 Innovation Hub
Three principal investigators with proven industrialization, microfluidics, and clinical immunoassay expertise.
An aggressive but staged path: non-dilutive funding first, regulatory clearance second, deployment third.
Pursuing Bill Gates Foundation Grand Challenges, NIH SBIR Phase I, and Ohio TVSF programs.
Reagent stabilization for ≥12-month shelf life (10-37°C); scFv-HRP fusion antibody scale-up.
F programs.
FDA Q-Submission, Class II 510(k) or De Novo path, CLIA Waiver design.
LMIC field deployment via WHO/Pasteur/CDC channels; US clinical rollout via Razor & Blade model.
Next-generation In Vitro Diagnostics, built on dual-flow Lab-on-a-Chip technology licensed from the University of Cincinnati.
Products described on this site are in development. They have not been cleared or approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. They are not yet available for sale.
© 2026 BQL Healthcare USA Inc. All rights reserved.